COVID-19 Impact on Sanofi
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Sanofi is a leader in developing vaccines for infectious diseases, and it has 73 manufacturing sites located in 32 countries. It’s portfolio that includes vaccines for polio, pertusis, Haemophilus influenzae type B, influenza, and meningitis, as well as travel vaccines. Sanofi’s COVID-19 response includes sarilumab, recombinant and mRNA vaccines.
Scope
This 32-page PowerPoint based report gives an important expert analysis on how COVID-19 will affect Sanofi. Findings are based on the industry’s most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Key Highlights
Reasons to Buy
An overview of how Sanofi will be affected by the COVID-19 pandemic.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.